{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:13:16Z","timestamp":1778947996284,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.survophthal.2025.09.022","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:10:53Z","timestamp":1759504253000},"page":"271-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to \u201cAdditional observations on ROCK inhibitors: reticular corneal epithelial edema\u201d"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6972-5355","authenticated-orcid":false,"given":"Christin","family":"Henein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jit Kai","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Steel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajjad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananth","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi G.","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng Tee","family":"Khaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2025.09.022_bib1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ajo.2019.06.016","article-title":"Netarsudil\/Latanoprost Fixed-Dose combination for elevated intraocular pressure: Three-Month data from a randomized phase 3 trial","volume":"207","author":"Asrani","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.022_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ophtha.2014.08.022","article-title":"Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure","volume":"122","author":"Bacharach","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2025.09.022_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","article-title":"Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: rho kinase elevated IOP treatment trial (ROCKET-2)","volume":"200","author":"Kahook","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.022_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","article-title":"Once-Daily netarsudil versus Twice-Daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study","volume":"204","author":"Khouri","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.022_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2023-001449","article-title":"Effect of ripasudil after trabeculectomy with mitomycin C: a multicentre, randomised, prospective clinical study","volume":"9","author":"Muhlisah","year":"2024","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.022_bib6","unstructured":"Pharmaceuticals A. Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension (ROCKET-3) 2016 [Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02246764."},{"key":"10.1016\/j.survophthal.2025.09.022_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.022_bib8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4103\/IJO.IJO_1340_23","article-title":"Comparison of safety and efficacy of netarsudil 0.02% and bimatoprost 0.01% monotherapy and combination therapy in primary open-angle glaucoma and ocular hypertension","volume":"72","author":"Shahid","year":"2024","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.022_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00417-023-06192-0","article-title":"Mercury-3: a randomized comparison of netarsudil\/latanoprost and bimatoprost\/timolol in open-angle glaucoma and ocular hypertension","volume":"262","author":"Stalmans","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.022_bib10","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/aos.12829","article-title":"One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension","volume":"94","author":"Tanihara","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2025.09.022_bib11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.022_bib12","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/aos.12599","article-title":"Intra-ocular pressure-lowering effects of a rho kinase inhibitor, ripasudil (K-115), over 24\u202fh in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study","volume":"93","author":"Tanihara","year":"2015","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.09.022_bib13","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1007\/s12325-023-02534-w","article-title":"Crossover randomized study of pharmacologic effects of Ripasudil-Brimonidine Fixed-Dose combination versus ripasudil or brimonidine","volume":"40","author":"Tanihara","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.survophthal.2025.09.022_bib14","unstructured":"Walters T.R., Ahmed I.I.K., Lewis R.A., Usner D.W., Lopez J., Kopczynski C.C., et al. Once-Daily Netarsudil\/Latanoprost."}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725001869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725001869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:28:58Z","timestamp":1778945338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625725001869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0039625725001869"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.09.022","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to \u201cAdditional observations on ROCK inhibitors: reticular corneal epithelial edema\u201d","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}